Printer Friendly

Agile incurs higher net loss of USD5.2m for Q4 2016.

M2 PHARMA-March 9, 2017-Agile incurs higher net loss of USD5.2m for Q4 2016

(C)2017 M2 COMMUNICATIONS

Pharmaceutical company Agile Therapeutics Inc (NasdaqGM:AGRX) stated on Wednesday that it recorded a net loss of USD5.2m (USD0.18 per basic share) for the three months ended 31 December 2016.

This marks a fall in earnings when compared with a net loss of USD3.9m (USD0.17 per basic share) for the quarter ended 31 December 2015.

R&D expenses of USD5.5m were recorded for the quarter ended 31 December 2016, a decline over USD6.9m for the comparable period in 2015, which was primarily due to decreased clinical development expenses as its Phase 3 clinical trial for Twirla moved closer to completion.

As of 31 December 2016, the company announced USD48.8m of cash and cash equivalents, a rise versus USD34.4m of cash and cash equivalents as of 31 December 2015.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Financial report
Date:Mar 9, 2017
Words:165
Previous Article:Patient Education Improves Colonoscopy Preparation; May Reduce Need for Repeat Screenings, Study Finds.
Next Article:Allergan files sNDA with the US FDA for VRAYLAR treatment for schizophrenia in adults.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters